@article{S de Guibert_A Jaccard_M Bernard_P Turlure_D Bordessoule_T Lamy_2006, place={Pavia, Italy}, title={Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma}, volume={91}, url={https://haematologica.org/article/view/3905}, DOI={10.3324/%x}, abstractNote={We report on a series of 24 patients with newly diagnosed mantle cell lymphoma treated with four to six courses of DHAP-rituximab followed by autologous stem cell transplantation for patients <65 years. Three-year overall survival (OS) and event free survival (EFS) rates were 69% and 65% respectively, for the 24 patients. In intent-to-treat analysis, 3-year OS and EFS were 75% and 76% for the 17 patients &lt; 65 years old. This treatment is quite feasible and compares favourably with other regimens.}, number={3}, journal={Haematologica}, author={S de Guibert and A Jaccard and M Bernard and P Turlure and D Bordessoule and T Lamy}, year={2006}, month={Mar.}, pages={425-426} }